Strengthening the Production System and Strategic Investment

「In April 2026, the new pharmaceutical manufacturing building at the Gunma Plant of consolidated subsidiary アルフレッサ ファーマ株式会社, headquartered in Chuo-ku, Osaka, became operational after construction had proceeded for some time. In addition to strengthening the production structure for small-molecule pharmaceuticals, this will enable full-scale entry into contract manufacturing of highly potent drug products and contract inspection, packaging and testing of sterile products.」

「In February 2026, consolidated subsidiary アルフレッサ ファーマ株式会社 (Head office: Chuo-ku, Osaka) launched the anaphylaxis rescue treatment Neffy® nasal spray 1 mg/2 mg (generic name: adrenaline) in Japan.」

「In September 2025, consolidated subsidiary アルフレッサ ファーマ株式会社, headquartered in Chuo-ku, Osaka, obtained manufacturing and marketing approval in Japan for Neffy® nasal spray 1 mg/2 mg, an adjunctive treatment for anaphylaxis. Its generic name is adrenaline.」

「In July 2024, the company began construction of a new pharmaceutical manufacturing building at the Gunma Plant of consolidated subsidiary アルフレッサ ファーマ株式会社, scheduled to be established in Ota, Gunma Prefecture, using funds raised through the social bonds issued by the company in December 2023.」

「In January 2024, アルフレッサ ファーマ株式会社 completed detailed design work for a new pharmaceutical manufacturing building at its Gunma Plant. Construction of the building will increase production capacity for small-molecule pharmaceuticals and enable full-scale entry into contract manufacturing of highly potent drug products and contract inspection, packaging and testing of sterile products.」

「In December 2023, as a funding measure to help create social value, the company issued social bonds totaling ¥20 billion to finance the construction and operation of a new logistics center in Tsukuba, Ibaraki Prefecture, and a pharmaceutical manufacturing building in Ota, Gunma Prefecture.」

「In December 2022, consolidated subsidiaries アルフレッサ ファーマ株式会社, headquartered in Chuo-ku, Osaka, and サンノーバ株式会社, headquartered in Ota, Gunma Prefecture, entered into an absorption-type merger agreement under which アルフレッサ ファーマ株式会社 would be the surviving company, and merged effective 1 April 2023.」

「In December 2022, アルフレッサ ファーマ and サンノーバ株式会社 entered into an absorption-type merger agreement, under which アルフレッサ ファーマ would be the surviving company, effective 1 April 2023.」

「In May 2022, consolidated subsidiaries アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka; hereinafter “アルフレッサ ファーマ”) and サンノーバ株式会社 (head office: Ota, Gunma) reached a basic agreement on a merger by absorption, with アルフレッサ ファーマ as the surviving company, and aim to complete the integration in April 2023.」

「In May 2022, consolidated subsidiaries アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka) and サンノーバ株式会社 (head office: Ota, Gunma) reached a basic agreement on a merger by absorption, with アルフレッサ ファーマ株式会社 as the surviving company.」

「The company acquired 5 products through a company split involving universal succession on 1 December 2021 and plans to acquire the remaining 6 products through a business transfer involving individual succession from fiscal 2022 onward. However, because the individual acquisition costs and other items are immaterial and difficult to calculate, the transactions are treated as a single business combination.」

「The segment reported net sales of ¥22,864 million and operating income of ¥1,096 million for the cumulative second quarter, compared with net sales of ¥20,476 million and operating income of ¥73 million in the same period of the previous year. This reflected contributions from long-listed products whose marketing approvals had been acquired in the previous fiscal year, higher sales of infectious-disease rapid-test kits, including the Alsonic® COVID-19 Ag SARS-CoV-2 antigen rapid-test kit launched in March 2021, and solid contract manufacturing performance.」

「The segment reported net sales of ¥11,078 million and operating income of ¥534 million for the cumulative first quarter, compared with net sales of ¥9,695 million and an operating loss of ¥19 million in the same period of the previous year. This reflected contributions from long-listed products whose marketing approvals had been acquired in the previous fiscal year, higher sales of infectious-disease rapid-test kits, including the Alsonic® COVID-19 Ag SARS-CoV-2 antigen rapid-test kit launched in March 2021, and solid contract manufacturing performance.」

「In February 2021, アルフレッサ ファーマ agreed with DAIICHI SANKYO COMPANY,LIMITED to acquire the marketing approvals, assets and other items relating to 11 long-listed products and 19 presentations manufactured and marketed by DAIICHI SANKYO COMPANY,LIMITED, and entered into an agreement for the transfer of assets and other items. In addition, in February 2021, アルフレッサ ファーマ acquired from ONO PHARMACEUTICAL CO.,LTD. the marketing approval for Kinedak tablets, manufactured and marketed by ONO PHARMACEUTICAL CO.,LTD.」

「As part of its effort to expand products in line with group needs, アルフレッサ ファーマ株式会社, a consolidated subsidiary, obtained manufacturing and marketing approval for the Nescoat® Cp Auto calprotectin kit to support assessment of the condition of ulcerative colitis and began selling it in October 2019. The product became eligible for reimbursement under Japan’s health insurance system on 1 May 2020.」

「In the pharmaceutical and other manufacturing business, we continue to implement the priority measures identified under the “19-21 Medium-Term Management Plan” to strengthen group synergies and achieve further scale: “Promoting safe, secure, and sincere manufacturing,” “Expanding products in line with group needs,” “Expanding contract manufacturing and the pharmaceutical API business,” and “Expanding overseas operations.”」

「As part of its efforts to “expand products in line with group needs,” consolidated subsidiary アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka) obtained marketing approval for the “ネスコート®Cp オート” calprotectin kit as an aid in assessing the condition of ulcerative colitis and began marketing it in October 2019. The product became eligible for reimbursement under Japan’s health insurance system on 1 May 2020.」

「In the pharmaceutical and other manufacturing business, we are implementing the priority measures identified under the “19-21 Medium-Term Management Plan” to strengthen group synergies and achieve further scale: “Promoting safe, secure, and sincere manufacturing,” “Expanding products in line with group needs,” “Expanding contract manufacturing and the pharmaceutical API business,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we are implementing the priority measures identified under the “19-21 Medium-Term Management Plan” to strengthen group synergies and achieve further scale: “Promoting safe, secure, and sincere manufacturing,” “Expanding products in line with group needs,” “Expanding contract manufacturing and the pharmaceutical API business,” and “Expanding overseas operations.”」

「As part of its effort to expand products in line with group needs, アルフレッサ ファーマ株式会社 obtained manufacturing and marketing approval on 5 June of the current year for the Nescoat® Cp Auto calprotectin kit as an in-vitro diagnostic for use in supporting assessment of the condition of ulcerative colitis. On 27 June of the current year, it also launched Neskeep®, an absorbable tissue spacer for radiation therapy.」

「The company entered into an agreement in July 2018 to acquire the marketing approvals, assets and other items relating to 41 long-listed products and began manufacturing and marketing some of the products in March 2019.」

「As part of its effort to expand the product lineup and strengthen sales capabilities, consolidated subsidiary アルフレッサ ファーマ株式会社 entered into an agreement in July 2018 to acquire, on or after 1 March 2019 as scheduled, the marketing approvals, assets and other items relating to 41 long-listed products marketed in Japan by DAIICHI SANKYO COMPANY,LIMITED and its subsidiary 第一三共エスファ株式会社.」

「As part of its effort to expand the product lineup and strengthen sales capabilities, consolidated subsidiary アルフレッサ ファーマ株式会社 entered into an agreement to acquire, on or after 1 March 2019 as scheduled, the marketing approvals, assets and other items relating to 41 long-listed products marketed in Japan by DAIICHI SANKYO COMPANY,LIMITED and its subsidiary 第一三共エスファ株式会社.」

「In the pharmaceutical and other manufacturing business, we continue to pursue the priorities set out in the 16-18 Medium-Term Management Plan: promoting safe, secure and sincere manufacturing; promoting contract manufacturing and the API business; expanding the product lineup and strengthening sales capabilities; and expanding overseas operations. As part of the effort to expand the product lineup and strengthen sales capabilities, on 31 July 2018, consolidated subsidiary アルフレッサ ファーマ株式会社 entered into an agreement to acquire the marketing approvals and assets and other items relating to 41 long-listed products marketed in Japan by DAIICHI SANKYO COMPANY,LIMITED and its subsidiary 第一三共エスファ株式会社.」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In the pharmaceutical and other manufacturing business, we continued to implement the segment-specific priority measures under the 16-18 Medium-Term Management Plan: “Promoting contract manufacturing and the active pharmaceutical ingredient business,” “Expanding the product lineup and strengthening sales capabilities,” and “Expanding overseas operations.”」

「In November 2016, 青島耐絲克医材有限公司, a subsidiary of アルフレッサ ファーマ株式会社, which is a consolidated subsidiary of the company, completed a new medical-device factory building at its site in Qingdao, Shandong Province, China, meeting international standards.」

「In April 2016, the company acquired the pharmaceutical and other manufacturing and marketing business of サンノーバ株式会社, a subsidiary of Eisai Co.,Ltd. headquartered in Bunkyo-ku, Tokyo, and began operations as a consolidated subsidiary.」

「In the pharmaceutical and other manufacturing business, we will strengthen our production structure and make strategic investments to expand the business. In addition to アルフレッサ ファインケミカル株式会社, which became a consolidated subsidiary in April 2015 and produces active pharmaceutical ingredients (APIs), we expanded the scale of the business by making サンノーバ株式会社, which undertakes contract manufacturing of pharmaceuticals and other products under advanced production and quality-control systems, a consolidated subsidiary in the fiscal year ending March 2017. We will also invest in facilities to expand production capacity.」